Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 11/20 | 0.42 |
| ▸ | PPARA | Q07869 | 11/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312435 | 0.84 | CYP2C19 (0.45) | CYP2C19PPARGPPARATSHRALDH1A1 | |
| SCHEMBL585488 | 0.83 | PPARG (0.53) | CYP2C19PPARGPPARA | |
| SCHEMBL13059499 | 0.82 | ALDH1A1 (0.52) | PPARGPPARATSHRALDH1A1NPSR1 | |
| SCHEMBL7329105 | 0.81 | TSHR (0.44) | CYP2C19PPARGPPARATSHRALDH1A1 | |
| SCHEMBL11667295 | 0.81 | CYP2C19 (0.45) | CYP2C19PPARGPPARA | |
| SCHEMBL3085599 | 0.81 | CYP2C19 (0.45) | CYP2C19PPARGPPARA | |
| SCHEMBL1326852 | 0.79 | CYP2C19 (0.44) | CYP2C19PPARGPPARA | |
| SCHEMBL11513552 | 0.74 | MTNR1A (0.46) | CYP2C19PPARGPPARATSHRALDH1A1 | |
| SCHEMBL10204793 | 0.73 | GAA (0.53) | CYP2C19TSHRALDH1A1MTNR1AMTNR1B | |
| SCHEMBL8669698 | 0.73 | ATM (0.41) | CYP2C19PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066443-B1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-8536344-B2 | Metathesis catalysts | UMICORE AG & CO. KG (DE) | 2013-09-17 | — | — | US | disclosed |
| US-20130211096-A1 | Novel Metathesis Catalysts | ARLT DIETER (DE) | 2013-08-15 | — | — | US | disclosed |
| US-8288558-B2 | Metathesis catalysts | UMICORE AG & CO. KG (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20100113795-A1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-2066443-A1 | NOVEL METATHESIS CATALYSTS | Umicore AG & Co. KG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008034552-A1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113795-A1 | NOVEL METATHESIS CATALYSTS | CYP1B1, CYP51A1, CYP1A1 | CYP2C19 75/4885PPARG 4711/4885PPARA 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.